SCHEMBL4701668

SCHEMBL4701668

O=C(NCc1ncc(C(=O)O)cc1Cl)NC1c2ccccc2CCc2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
OPRM1 P35372 4/20 0.37
OPRK1 P41145 3/20 0.37
OPRL1 P41146 1/20 0.37
PPIA P62937 2/20 0.37
DHODH Q02127 1/20 0.37
ENPP2 Q13822 1/20 0.36
TBXAS1 P24557 1/20 0.36
HTR2C P28335 1/20 0.36
SLC6A3 Q01959 1/20 0.36
TBXA2R P21731 1/20 0.36
EPHX2 P34913 2/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
P2RX7 Q99572 1/20 0.35
HTT P42858 2/20 0.35
OPRD1 P41143 1/20 0.35
GCK P35557 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4702800 0.89 KMT2A (0.40) ALDH1A1OPRM1OPRK1OPRL1PPIA
SCHEMBL4702365 0.86 OPRM1 (0.34) ALDH1A1OPRM1OPRK1OPRL1PPIA
SCHEMBL6387792 0.84 ROCK2 (0.38) PPIATBXAS1P2RX7
SCHEMBL6387406 0.83 ALDH1A1 (0.47) ALDH1A1TAS1R3TAS1R1
SCHEMBL4758046 0.82 EPHX2 (0.49) ALDH1A1OPRM1OPRK1OPRL1PPIA
SCHEMBL4699759 0.81 TAS1R3 (0.36) ALDH1A1OPRM1OPRK1OPRL1DHODH
SCHEMBL4698540 0.81 OPRM1 (0.35) ALDH1A1OPRM1OPRK1OPRL1TAS1R3
SCHEMBL4756002 0.80 ALDH1A1 (0.39) ALDH1A1OPRM1OPRK1OPRL1ENPP2
SCHEMBL6389721 0.76 ROCK2 (0.37) ALDH1A1TBXAS1
SCHEMBL6391029 0.75 ROCK2 (0.38) ALDH1A1TBXAS1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458684-B1 THERAPEUTIC HETEROCYCLES AS BRADYKININ B2 RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2008-01-16 EP disclosed
US-20050245503-A1 Therapeutic heterocycles ASTRAZENECA AB (SE) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245503-A1 Therapeutic heterocycles OPRK1, RECQL, OPRM1 ALDH1A1 2117/4885OPRM1 3/4885OPRK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.